Lebrikizumab in moderate-to-severe atopic dermatitis: real-world patient-reported outcomes & mHealth engagement on the NAVETA ePROM platform
Perelló Alzamora MR, Llull A, Motis C, Gracia J, Vanrell E, Munar Llabrés A, Mercadal-Orfila G, Salvador Pareja S, Maestre Fullana MA, Vila Payeras A, Bello Crespo M, Rocamora Durán V, Escrivá Sancho ME, López Sánchez P